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Abstract  
Amyotrophic Lateral sclerosis (ALS) is a fatal neurodegenerative disorder. We screened 608 
familial ALS exomes and identified 6 novel, or extremely rare, Annexin A11 mutations in 12 
individuals.  The novel p.D40G mutation which was absent from >60,000 exomes; 
segregated with disease in two kindreds, was present in two unrelated cases and all carriers 
shared a common haplotype.  Annexin A11-positive aggregates were abundant in spinal 
motor neurons and hippocampal axons in a D40G patient. Transfected cells expressing 
p.D40G and other N-terminal mutations had altered calcyclin binding while the p.R235Q 
mutant formed toxic, insoluble aggregates. Annexin A11 mutations accounted for ~1.2% of 
familial and ~1.7% of sporadic cases. Mutations in Annexin A11 highlight the role of 
defective cellular trafficking in the pathogenesis of ALS. 
 
Introduction  
Gene hunting in rare Mendelian disorders has been transformed by exome sequencing, 
particularly for autosomal recessive disorders [1]. This approach is also attractive for late-
onset autosomal dominant syndromes with short disease durations, such as Amyotrophic 
Lateral Sclerosis (ALS), in which DNA from multiple affected individuals in the same kindred 
is rare. ALS has a life-time risk of 1/400 and is characterized by degeneration of brain and 
spinal cord motor neurons resulting in progressive paralysis and death within an average of 
3 years [2]. 10% of cases are familial (FALS) and a causative gene mutation can be identified 
in ~60% of European kindreds [3]. Mutations in the same genes account for ~10% of 
sporadic ALS cases reflecting incomplete penetrance. Non-synonymous mutations in SOD1, 
TARDBP, FUS and an intronic hexanucleotide repeat expansion in C9ORF72 account for ~20% 
of ALS cases and the other genes for ~1-3% [4]. Exome sequencing has identified six ALS 
genes where mutations segregate with disease (VCP, PFN1, MATR3 and CHCHD10) or by 
genetic burden analysis (TUBA4A and TBK1) [5-11]. Here we analysed FALS exomes to 
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identify common founder non-synonymous variants present in multiple unrelated index 
cases to identify candidate ALS genes [12-14]. 
 
Exome sequencing, filtering and gene identification  
The exomes of 403 FALS index cases without mutations in known ALS genes were analyzed 
in an unbiased fashion. Successive filtering steps were used to identify single nucleotide 
changes present in 2 or more FALS cases but absent in the exomes of ~60,000 individuals in 
publicly available databases (1000 Genomes, NHLBI GO Exome Sequencing Project (ESP), UK 
10K, ExAC and 672 In-house UK exome controls, see Supplementary Information). Sixty 
novel heterozygous missense, nonsense or splice changing variants were shared by at least 
two index cases (Supplementary Table 1). As proof of methodology, the same approach was 
applied to 58 exomes with known mutations, which identified 6 mutations in three known 
ALS genes (SOD1, TARDBP or FUS).  
 
We then analyzed an independent replication cohort of 205 index FALS cases (and 47 where 
the mutation was known), which confirmed two of the novel variants in the discovery cohort 
and the total number of shared novel variants rose to 95 (Supplementary Table 1). The top 
novel variant was p.D40G (c.119A>G) in ANXA11 (Annexin A11, Refseq NM_145869) that, in 
addition to being found three times, also satisfied segregation criteria. Sanger sequencing of 
18 family members confirmed the presence of the mutation in another affected individual 
from each of two multi-generational British kindreds in the discovery cohort (Figs 1A-B). 
Four unaffected individuals also carried the mutation but three of these were in their forties 
and the average age of disease onset in these kindreds was 72 years. In the replicate cohort 
one Italian FALS index case also carried the D40G variant. Sanger sequencing a cohort of 180 
British sporadic ALS cases (SALS) identified one further p.D40G carrier. All five British D40G 
carriers share a common haplotype on the disease allele defined by 8 SNPs and 2 
microsatellites spanning the locus confirming a common founder (Supplementary Figure 1).   
 
Additional ANXA11 variants identified in the discovery FALS cohort were two unrelated 
individuals carrying a c.112G>A, p.G38R variant (rs81930608) that was absent from local UK 
and Italian exome controls (n=4505). Although the p.G38R variant is present in 6/55261 
ExAC exomes it is still significantly associated with FALS in our cohort (p=0.007, 2-tailed 
Fishers exact test). In the replication cohort, novel p.G175R (c.523G>A) and p.R346C 
(c.1036C>T) variants were detected in two index cases. The p.G175R was also present in an 
affected sibling with ALS (Fig 1C) confirming segregation with disease. All coding exons of 
ANXA11 were Sanger sequenced in an additional 180 British SALS cases.  One individual 
carried a novel p.R235Q (c.704G.A) change and another case a p.G189E (c.566G>A) variant 
which is present in 14/33140 in European cases in ExAC (p=0.05) but is also present in one 
SALS case in the Biogen database ALSdB (http://chgv.org/alsdb/index.jsp). All but one of the 
ANXA11 variants identified here are predicted to be damaging by Polyphen (see 
Supplementary Table 2).  
 
Annexin A11 is a widely expressed, calcium-dependent phospholipid-binding protein 
(505AA, 56kDa) that belongs to the larger annexin family of 12 members (Interpro ID 
IPR001464). Each family member has four annexin domains many of which can complex a 
calcium ion facilitating binding to anionic cell membranes. Four of the six mutations in 
Annexin A11 cluster within the long N Terminus with p.G38R and p.D40G representing a 
mutation hotspot, implying that this region has functional importance. All mutation 
positions are completely conserved in mammals and those in the annexin domains are also 
conserved in all currently sequenced birds, amphibians and reptiles (Fig 1D).  
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Clinical Features and Neuropathology  
All patients with ANXA11 mutations had late disease onset (average 67 yrs) with a classical 
ALS phenotype without features of dementia (Supplementary Table 3). Five of six patients 
carrying the p.D40G variant had bulbar onset. Post mortem tissue was available from a SALS 
case carrying the p.D40G variant showing classical pathological features of ALS with a unique 
feature of large Annexin A11 immunoreactive inclusions that were absent from other ALS 
cases or controls (Fig 2). Spinal cord sections revealed marked neuronal loss within the 
anterior horns. There was marked myelin pallor and astrogliosis in the anterior and lateral 
corticospinal tracts. Many surviving motor neurons contained cytoplasmic inclusions positive 
for p62 and phospho-TDP-43 (Figure 2 A). Phospho-TDP-43 inclusions were also found in the 
medulla, temporal neocortex and hippocampus (data not shown). Annexin A11 staining of 
spinal cord sections showed numerous neuronal cytoplasmic inclusions (NCIs) in the 
perikaryon and proximal axon (Figures 2B-E). These included large-caliber tubular-shaped 
structures (Fig 2C-D) as well as skein-like (2B), filamentous and more complex basket-like 
inclusions (2E). Annexin positive NCIs were also evident in small numbers in the motor 
cortex, dentate gyrus of the hippocampus and temporal neocortex sometimes accompanied 
by abundant torpedo-like neuritic structures in the neuropil (Figure 2F). Staining for the 
amyloid precursor protein, Neurofilament, and β3 tubulin was negative. SALS devoid of 
known mutations and controls were negative for annexin NCIs (Fig 2G-H). Double 
fluorescent labelling of phospho-TDP-43 and annexin A11 showed no evidence of co-
localization (Fig 2I and J). Some annexin A11 positive aggregates were ubiquitinated (Figs 2K 
and L).  
 
Functional studies  
In order to understand the functional significance of these variants we undertook a series of 
cellular studies of mutations identified in our discovery exome set.  We generated 
ANXA11WT, ANXA11G38R ANXA11D40G and ANXA11R235Q tagged with hemagglutinin (HA) or GFP 
at the C-terminus. Constructs were expressed in mouse primary motor neurons (PMNs), 
human embryonic kidney 293 (HEK) and SH-SY5Y neuroblastoma cells. PMNs transfected 
with ANXA11-HAWT constructs showed nuclear and cytoplasmic localization. In the cytoplasm 
ANXA11 was present in larger vesicle-like structures, smaller foci structures (classified by 
size, see Supplementary Methods) and diffusely distributed throughout the soma, axons and 
dendrites (Fig 3A). Apart from ANXA11-HAR235Q, which was elevated in the cytoplasm, there 
was no evidence that the other mutations affected the distribution between the nucleus and 
cytoplasm (Fig 3B) [15]. The ANXA11-HAR235Q mutant appeared to aggregate into foci, was 
never associated with the vesicular-like structures and diffuse staining was absent (p<0.001) 
(Fig 3C). ANXA11-HAD40G had a similar pattern to WT but ANXA11-HAG38R displayed 
significantly less association with the vesicle-like structures (p=0.005). ANXA11-GFPR235Q 
expression in HEK cells showed marked aggregation into ubiquitin and p62 positive 
inclusions (Supplementary Figure 2) with high molecular weight species on western blot that 
were insoluble (Supplementary Figure 3) (p=0.007). SH-SY5Y cells transfected with ANXA11-
GFP demonstrated the ANXA11-GFPR235Q mutant to be toxic but not the other mutants 
(p=0.0001) (Supplementary Figure 4). We also investigated whether ANXA11 is self-
interacting by co-transfecting SH-SY5Y cells with either ANXA11-GFPWT and ANXA11-HAWT or 
ANXA11-GFPR235Q and ANXA11-HAWT (Fig 3D). The merge of WT-HA and WT-GFP showed 
nuclear and diffuse cytoplasmic staining as expected, however ANXA11-GFPR235Q cytoplasmic 
puncta and WT-HA did co-localize. This suggests mutant ANXA11 may act to recruit and 
sequester WT ANXA11, potentially in a dominant negative manner. 
 
Next we sought to determine whether there was an interaction between TDP-43 and 
Annexin A11. PMNs were cotransfected with the C-terminal fragment of TDP-43 (AA 208-
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414) tagged with GFP and each of the ANXA11-HA variants. The ANXA11-HAR235Q aggregates 
robustly colocalised with CTF-TDP-43-GFP four days post-transfection (Fig 4E). Furthermore, 
vesicle-like structures containing the ANXA11-HAD40G mutation appeared to significantly 
engulf TDP-43 aggregates that were not seen for the other mutations. 
 
N-terminal mutants disrupt binding of ANXA11 to Calcyclin  
Because residues 50-62 in Annexin A11 bind calcyclin (encoded by S100A6) and are close to 
the mutants G38R and D40G we sought evidence for any effect on their interaction. 
Calcyclin is a 10kDa protein that contains 2EF-hand calcium-binding motifs [16]. Alignment 
of all mammalian Annexin A11 orthologue sequences predicted that residues 38-45 and 50-
60 form dual amphipathic helices known to mediate calcium-dependent protein-membrane 
interactions [17] (Supplementary Figure 5A). Annexin A1 has a similar dual amphipathic helix 
structure that in the absence of calcium is embedded within the annexin core but is released 
on calcium activation and facilitates its binding to S100A11 [18, 19] (Sup Fig 5B-C). Using 
Jpred4 software the Annexin A11 G38R variant is predicted to create a new beta-sheet while 
D40G is predicted to severely reduce formation of the first amphipathic helix, thus both of 
these mutants may disrupt calcyclin binding but in different ways (Sup Fig 5D).  
 
In order to assess the effects of mutations in Annexin A11 on calcyclin binding we performed 
binding assays of ANXA11-GFPWT and the ANXA11G38R, D40G, G189E and R235Q mutants using a 
previously published in-vitro immuno-precipitation (IP) assay [20]. In brief, FLAG- Calcyclin 
and ANXA11-GFP WT and mutant constructs were transfected into HEK cells, lysates were 
mixed and activated with calcium, immunoprecipitation (IP) was performed with anti-FLAG 
antibody and the resulting western blot probed for GFP. As expected WT GFP co-
immunoprecipitated with calcyclin, that confirmed calcyclin–Annexin A11 binding. ANXA11-
GFPD40G severely disrupted calcyclin binding, as did ANXA11-GFPG189E and ANXA11-GFPR235Q 
mutants (Figure 4A). ANXA11-GFPG38R binding however was markedly increased compared to 
WT. Arginine is polar thus the p.G38R change could enhance the hydrophilic properties of 
the amphipathic helix that may explain enhanced calcyclin binding. D40G, on the contrary is 
a charged to hydrophobic modification that could account for reduced calcyclin interaction. 
No differences were observed in ANXA11 binding to other partners ALG2 and Sorcin 
(Supplementary Figure 6).  
 
IHC on spinal cord sections from the ALS patient carrying the D40G mutation were stained 
with anti-calcyclin antibody. Although there was no observable difference in neuronal 
staining between the ALS case and controls very high levels of calcyclin expression were 
detected in the cytoplasm of astrocytes in the lateral corticospinal tracts compared to 
controls (Figs 4Bi-iv). This is not a mutation-specific event as elevated calcyclin expression 
was also seen in sporadic ALS cases without known ALS gene mutations (Figs 4Bv-vi). 
Increased expression of calcyclin in astrocytes of the corticospinal tract has previously been 
reported in sporadic ALS cases as well as SOD1G93A transgenic mice [21, 22].  
 
We also explored the impact of calcyclin interaction on Annexin A11 solubility. FLAG-CACYWT 
was co-transfected with ANXA11-GFPWT or ANXA11-GFPR235Q in HEK cells and the subcellular 
distribution assessed by immunocytochemistry and solubility by western blot. Remarkably, 
the increase in calcyclin expression reduced levels of soluble WT and R235Q but it 
completely cleared insoluble ANXA11-GFPR235Q (Fig4C). This suggests that increasing calcyclin 
may inhibit ANXA11 expression or enhance ANXA11 clearance via a degradation pathway. 
Treating the cells with the ubiquitin proteasome inhibitor MG132 treatment for 24hrs 
restored ANXA11R235Q insolubility.  
 
6  
Discussion  
Using a stringent filtering strategy on large-scale FALS index case exome data we identified a 
non-synonymous mutation, D40G in Annexin A11 that segregates with disease in two large 
UK families and in two replicate FALS and SALS cohorts but is absent from >60,000 exomes. 
The G175R mutation segregated with disease in one kindred and several other ANXA11 
mutations were associated with ALS. The clinical phenotype was of late-onset classical ALS 
but 4 of 5 D40G cases had bulbar onset disease. Post mortem tissue from a D40G ALS case 
displayed abundant Annexin A11-positive aggregates within motor neurons in spinal cord 
and neurons and neuropil in the neocortex and hippocampus in addition to the classical 
features of neuronal loss, phospho-TDP-43 inclusions and astrogliosis.  
 
Following cellular transfection, the R235Q mutant formed detergent resistant ubiquitinated 
cytoplasmic aggregates that sequestered wild-type Annexin A11 and were cytotoxic.  The 
sequestering of wild-type Annexin A11 suggests that Annexin A11 may self-interact. 
Evidence for this exists from another annexin family member, Annexin A2, that forms 
hetero-tetramers via bridging with it’s N-terminal binding partner S100A10 [23]. Calcyclin is 
known to bind to Annexin A11 and to itself so could form a similar heterotetramer [24]. 
Although the R235Q mutant failed to bind to calcyclin over-expression of calcyclin 
completely cleared insoluble R235Q aggregates by facilitating proteasomal degradation. 
More subtle differences in calcyclin binding were also observed for other Annexin A11 
mutants. Calcyclin binding was inhibited by D40G and G189E mutations and consistently 
increased above wild-type for the G38R mutant. Calcyclin is known to play a role in 
proteostasis as it forms a functional complex with calcylcin binding protein (CACYBP) and the 
RING type E3 Ubiquitin Ligase SIAH-1 that regulates ubiquitination and degradation of 
synaptophysin and binds with alpha-synuclein [25, 26]. Therefore loss of calcyclin binding 
may result in an accumulation of cytoplasmic ANXA11 promoting its aggregation.  
 
We and others have shown that the levels of calcyclin are greatly increased in astrocytes in 
sporadic ALS cases as well as the one carrying the D40G mutation [21, 22]. Even though this 
phenomenon is not solely linked to Annexin A11 mutations, it raises the possibility that 
increased astrocytic calcyclin expression is a response to defective proteostasis. 
Interestingly, cells in which TDP43 is knocked-down demonstrate a significant increase in the 
expression of calcyclin transcripts [27]. Additionally, elevated calcyclin concentrations can 
form oligomers that have amyloidogenic properties that have been shown to seed SOD1 
aggregation [28].  
 
ANXA11 is a phospholipid binding protein, which may play a role in vesicle trafficking as it 
has been reported to play a role in apoptosis, exocytosis and cytokinesis [29]. ANXA11 co-
localises with calcyclin in the nuclear envelope during prophase of mitosis [30], however 
little is known about its role in post-mitotic neurons. From our study Annexin A11 does form 
vesicle-like structures in PMNs, which suggests a role for Annexin A11 in vesicular transport. 
Recent evidence has found that Annexin A11 plays an important structural role in regulating 
the delivery of vesicular cargoes from the endoplasmic reticulum to the Golgi apparatus 
which is mediated through its binding to ALG2 to stabilize Sec31A [31]. In our study, Annexin 
A11 mutations did not directly affect ALG2 binding it is therefore more likely that the mutant 
alleles disrupt vesicular trafficking by altered binding to calcyclin.  
 
We have identified 6 novel, or extremely rare, ANXA11 mutations in 12 individuals, which 
account for ~1.2% of familial and 1.7% for sporadic ALS cases. The mutations alter binding to 
calcyclin, which can lead to cytoplasmic aggregation in transfected cells and neuronal 
cytoplasmic inclusions in a patient carrying the D40G mutation at post mortem. The 
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identification of ANXA11 mutations highlights the significance of calcium binding proteins 
and intracellular trafficking in ALS pathobiology [32]. Further work investigating how 
mutations affect the folding of annexin A11, its binding to calcyclin and the effect on 
vesicular transport and TDP-43 aggregation will clarify the underlying disease mechanisms. 
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Supplementary Materials and Methods 
 
DNA Samples 
Full patient consent was provided by FALS index patients and control individuals for research 
purposes. All patients had a diagnosis of definite or probable ALS based on revised El Escorial criteria 
(Brooks, 2000) with at least one relative known to have ALS+/-FTD.  All FALS were pre-screened for 
known causative ALS genes and individuals carrying mutations in SOD1, C9ORF72 (GGGGCC 
expansion), TARDBP, FUS, PFN1, UBQLN2, MATR3, CHCHD10, TBK1, OPTN, VAPB and VCP were 
excluded from the study. The discovery cohort was comprised of 403 FALS sourced from the UK (163), 
Italy (97), the United States (90), Spain (30), Ireland (17), Belgium (3) and the Netherlands (3).,  An 
additional 58 subjects were exome captured where the primary causative mutation had previously 
been determined (FUS, TARDBP or SOD1). Furthermore, DNA of at least one affected family member 
was available from 27 index cases and was exome sequenced in tandem for segregation analysis.   
The replication cohort consisted of a total of 204 cases pre-screened for known ALS genes (above) 
from the United States (132), Italy (25), the UK (20), Germany (20), and Canada (7). An additional 47 
subjects were exome captured where the likely pathogenic mutation has already been determined, 
plus the affected relatives of 28 of the index cases in the replication cohort. Sequence data for 109 
cases in the replication cohort were obtained, with permission, from the dbGAP repository (NIH 
Exome Sequencing of Familial Amyotrophic Lateral Sclerosis, NINDS, phs000101.v4.p1, Traynor) 
 
Exome Sequencing and Bio-informatic Analysis  
Exome sequencing paired-end FASTQ files were aligned to the hg19 human reference using NovoCraft 
Novoalign, and variants called with samtools v1.1 mpileup. VCF files were filtered at DP>=10 and GQ 
>=20, and normalized with bcftools v1.1 norm. Functional annotation and matches to 1000genomes 
and 672 local control exomes were added with table_annovar.pl (Wang K, Li M, Hakonarson H. 
ANNOVAR: Functional annotation of genetic variants from next-generation sequencing data Nucleic 
Acids Research, 38:e164, 2010). Matches to other public variant resources (ExAC, ESP, UK10K, 
dbSNP142) were added via custom perl scripts.  Effects on splicing were assessed using Netgene2 
(Brunak, S., Engelbrecht, J., and Knudsen, S., Prediction of Human mRNA Donor and Acceptor Sites 
from the DNA Sequence. Journal of Molecular Biology, 1991, 220, 49-65.) but no significant changes 
found between the wild type or any ANXA11 variant sequence.  
All novel variants (defined as absent from ExAC (http://exac.broadinstitute.org/), ESP 
(http://evs.gs.washington.edu/EVS/), UK10K (http://www.uk10k.org/) and 772 In-house exome 
controls) shared between unrelated index cases where at least one sample had a GQ<90 were 
manually inspected using a combination of the Integrative Genomics Viewer and UCSC Blat, and 
without exception rejected due to either misalignment of reads from close paralogues or local 
alignment error adjacent to common indels.  It is possible that some of the remaining variants found 
in two samples are also false positives, but those variants shared by three or more cases have all been 
verified by this method.  
 
Genetics Screening 
All coding exons of ANXA11 (Refseq ID NM_145869) were amplified using standard polymerase chain 
reaction procedures. At least 100bp of flanking intronic sequence was included to detect splice site 
mutations. Amplicons were directly sequenced with Big-Dye Terminator v1.1 on an ABI3130 genetic 
analyzer (Applied Biosystems Pty Ltd, Warrington, UK) and sequence chromatograms analyzed for 
mutations using Sequencher 4.10 directly by eye (Gene Codes Corporation, Ann Arbor, Michigan, 
USA). Reconfirmation of novel mutations was conducted by re-dilution of stock DNA and re-PCR and 
direct sequencing. Rare variant positions in ANXA11 were also filtered against 3596 Italian exome 
controls. Nine hundred and nine local control UK samples matched for sex and age were assayed for 
ANXA11 genomic SNP positions for the G38R, D40G, G189E and R235Q mutations using KASPar 
genotyping methods by LGC Genomics (LGC Genomics, Teddington, UK).  
 
Plasmids and Cloning 
A cDNA encoding ANXA11 was amplified from pEGFP-C3/ANXA11 (Tomas and Moss, 2003) with the 
following pair of oligonucleotides with a BamHI site (underlined): 5’-
TAGGATCCACCATGAGCTACCCTGGCTATCC-3’ (sense) and 5’-
GCGGATCCGAGTCATTGCCACCACAGATCTT-3’ (antisense). The DNA fragment obtained was subcloned 
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into the pCR-BluntII-TOPO (Invitrogen). To construct pANXA11-SGFP2, a BamHI fragment from pCR-
Blunt II-TOPO/ANXA11 was inserted into the BamHI site of pSGFP2-N-SGG (Shibata et al. 2010). Single 
amino acid changes (G38R, D40G and R235Q) were introduced into pANXA11-SGFP2 by PCR-based 
site-directed mutagenesis. To construct pFLAG-S100A6, an EcoRI fragment of pCR2.1 TOPO/S100A6 
(kindly provided by Dr. Kiyotaka Hitomi, Nagoya University, Japan) was inserted into the EcoRI site of 
pCMV3xFLAG-B (Katoh et al. 2003). A cDNA encoding sorcin was amplified from human fetus cDNA 
library (Clontech) and subcloned into the pCMV-Tag 2A (Stratagene) to construct pFLAG-sorcin. An 
expression vector encoding ALG-2 N-terminally tagged with FLAG (pFLAG-ALG-2 RNAiR) was described 
previously (Okumura et al. 2009). 
ANXA11 expression vectors (Gateway pcDNA3.1/nV5-DEST, Invitrogen) encoding c-terminal HA 
tagged ANXA1 wild type (WT), G38R, D40G and R235Q mutants were used in this study. Site-directed 
mutagenesis was performed according to the manufacturer’s protocol (Quickchange II Site-Directed 
Mutagenesis Kit, Stratagene) using a ANXA11-HA tagged pDONR221 entry clone plasmid to produce 
constructs harboring the novel mutants identified in this study. The pDONR221-ANXA11 mutant 
constructs were then recombined with pcDNA3.1/nV5-DEST to create the final mutant expression 
constructs. All constructs were verified by sequencing.  
 
Antibodies 
Mouse monoclonal anti-GFP at 1/2000 (cat.no sc-9996, Santa Cruz, Dallas, USA), mouse monoclonal 
anti-GAPDH (cat.no G8795, Gillingham, UK) and mouse monoclonal Histone H3 (cat.no 96C10, New 
England Biolabs Hitchin, UK) were used for detecting lysate, soluble and insoluble fractions on 
Western blot from NP40 insolubility assays. Mouse monoclonal anti-GFP at 1/2000 (cat.no sc-9996), 
FLAG-M2 (mouse) was used to detect FLAG-ALG2 and FLAG-Sorcin and rabbit FLAG (cat.no. F7425, 
Sigma) were using in the Annexin A11:calcyclin binding assays. Polyclonal Rabbit Anti-ANXA11 (cat.no. 
10479-2-AP, Proteintech, Manchester, UK) was used for ANXA11R235Q staining of HEK cells 
(Supplementary Figure 2) and spinal cord of the D40G SALS patient, SALS patient devoid of known ALS 
causing mutation and controls. Polyclonal rabbit Anti-calcyclin (cat.no. 10245-1-AP, Proteintech) was 
utilized for IHC of patient and control post mortem tissue.  
 
Transfection of HEKS Cells  
HEK293T cells were maintained in DMEM with high glucose plus Glutamax (Life Technologies, Paisley, 
UK) with 10% fetal bovine serum,100 U/mL penicillin, and 100 mg/mL streptomycin in a water 
jacketed incubator at 5% CO2. For solubility fractionation, transfections were performed in 12-well 
plates with 500 ng of plasmid DNA and 1.5 mL of Fugene HD (Promega, Southampton, UK) per well, as 
per the manufacturer’s protocol. For immunofluorescence, HEK293T cells were plated at 25,000 
cells/cm2 on 13 mm diameter, 1.5-mm-thickness coverslips coated with poly-D-lysine (Sigma-Aldrich, 
Dorset, UK) in 24-well plates and transfected with 250 ng of DNA and 0.75 mL of Fugene HD. 
 
Cell Survival GFP FACS Analysis  
For cell survival assay, SH-SY5Y cells were trypsinised and stained with Calcein Violet 450AM Viability 
Dye (500 nM, eBioscience) for 30 min at room temperature. After washed twice with PBS, cells were 
resuspended in PBS and analysed with BD FACS CantoII (BD Biosciences). 
 
FLAG-S100A6 and ANXA11-GFP Binding Assays  
HEK293 YS14 cells (a sub-cloned HEK293 cell line) (Shibata et al. 2007) which had been plated on the 
previous day at a density of 2 x 106 cells per 10 cm dish were transfected with expression plasmids 
using Polyethyleneimine (150 μg) (Polysciences) and then cultured for 24 hr. To attain equivalent 
expression level, the following amounts of plasmid DNA for SGFP2-fused proteins were used: pSGFP2-
N-SGG, 3 μg; pANXA11WT-SGFP2, 5 μg; G38R, 6 μg; D40G, 7 μg; G189E, 6 μg; R235Q, 10 μg. The cells 
were washed and harvested with PBS, suspended in 470 μL per 10 cm dish (for cells expressing 
SGFP2-fused proteins) or in 350 μL per 10 cm dish (for cells expressing FLAG-tagged proteins) of lysis 
buffer (20 mM HEPES-KOH, pH 7.2, 142.5 mM KCl, 2.5 mM MgCl2) containing 0.2% Triton X-100, 10 
μM EGTA, protease inhibitors (1 μM E64, 3 μg/mL leupeptin, 0.1 mM pefabloc, 2 μM pepstatin A, 0.2 
mM PMSF) and phosphatase inhibitors (50 mM NaF, 10 mM β-glycerophosphate, 1 mM Na3VO4). 
After 30 min on ice, the cell lysates were centrifuged at 15,000 g for 10 min at 4°C. The cleared lysates 
of the cell expressing SGFP2-fused proteins were divided into aliquots of 200 μL and mixed with 100 
μL of the cleared lysates of the cells expressing FLAG-tagged proteins. Twenty μL of the mixture was 
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taken as input. The samples were rotated at 4°C for 90 min in the presence of 100 μM of CaCl2, mixed 
with 0.8 μg of mouse antibody against FLAG (M2) and rotated at 4°C for further 60 min. Then the 
samples were incubated overnight at 4°C with 10 μL of Dynabeads Protein G (Novex, Invitrogen). The 
beads were collected using a magnet and washed twice with 500 μL of lysis buffer containing 0.1% 
Triton X-100 and 100 μM CaCl2. Washed beads were boiled for 5 min in 56 μL of 1x SDS-PAGE sample 
buffer. Four μL of input and 8 μL of IP (for detection of FLAG-tagged proteins) or 1.2 μL of input and 
12 μL of IP (for detection of SGFP2-fused proteins) were run on a western blot. 
 
FLAG-Calcyclin and ANXA11-GFP over-expression in HEK cells 
500ng of ANXA11-GFPWT and ANXA11-GFPR235Q constructs were co-transfected with 500ng of FLAG-
Calcyclin in a 6 well dish of HEK cells plated at 25,000 cells/cm2. Untreated ANXA11-GFPWT and 
ANXA11-GFPR235Q were co-transfected with empty pEGFP-C1 vector (Clonetech Pty Ltd, Mountain 
View, California, USA). Duplicate wells of ANXA11-GFPWT and ANXA11-GFPR235Q transfected cells were 
also treated with 0.5μM MG132 24hrs before harvesting (48 hours post transfection). Cells were 
harvested and processed as per the NP40 insolubility assay listed below. 
 
Primary Motor Neuron (PMN) Cultures  
Motor neurons were isolated from mouse embryos, cultured and transfected as described (Fallini et 
al, Mol. Neurodeg., 2010). Cells were fixed 1 or 4 days after transfection and processed for 
immunofluorescence. After antigen retrieval in citrate buffer for 20 minutes and blocking in 5% 
bovine serum albumin for 1 hour, cells were hybridized overnight at 4°C with HA primary antibody 
(Covance, 1:1000) Alexa488 or Alexa594-conjugated secondary antibodies (Jackson Immunoresearch) 
were incubated for 1 hour at room temperature. 
 
Protein Fractionation and Insolubility Assay 
ANXA11-GFP WT and mutant construct transfected HEK cells were harvested at 48 wells post-
transfection and fractionated using a NP40 solubility assay as described previously (Smith et.al 
Neurobiology of Aging 2015). Lysate and soluble fractions were quantified using a BSA standard 
protein assay and 5ug of lysate and soluble fractions analysed by Western blotting. The same volume 
of insoluble fraction was loaded as per cell lysate. Nitrocellulose membranes were probed with 
mouse monoclonal anti-GFP at 1/2000 dilution, mouse monoclonal ant-GAPDH 1/2000 dilution and 
mouse monoclonal Histone H3 1/1000 dilution in 1% Skim Milk and PBS-Tween. Band intensities were 
quantified using Image J (http://imagej.nih.gov/ij/). 
 
Statistical Analysis 
Statistical analysis of PMN immunofluorescence data and NP40 insolubility data was performed with 
Graphpad Prism software.  Normality of the datasets was assessed with the D’Agostino-Pearson test. 
One-way ANOVA with Dunnett’s post hoc test or Kruskal-Wallis with Dunn’s post hoc test were 
performed depending on normality.  
 
Mutation modelling and Jpred Analysis  
The Refseq protein database was searched with human ANXA11 (NP_001148.1) via BlastP at the NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The highest matching sequence per vertebrate species from 
the first 250 results was aligned with all others using Muscle 
(http://www.ebi.ac.uk/Tools/msa/muscle/).  Sequences were removed if they had a better reciprocal 
match to a different human annexin gene or if they contained significant numbers of gaps, 
mismatching regions or consecutive “X”s, implying incomplete or mistranslated sequence. Fish were 
also excluded, as they consistently showed significant divergence along the majority of the N-
terminus, and with the exception of the first 20 amino acids a satisfactory alignment to other Classes 
could not be obtained. The resulting multiple alignment was hand edited in GeneDoc and submitted 
to JPred4 (http://www.compbio.dundee.ac.uk/jpred4/) for secondary structure prediction. 
Predictions were also made for the ALS-associated variants G38R and D40G, and the non-ALS D40H 
negative-control variant (rs368751524, found once in the ExAC dataset) by replacing every amino acid 
in the multiple alignment with the variant residue. Possible amphipathicity of any resulting alpha 
helices was tested by submitting the sequences to Helixator 
(http://www.tcdb.org/progs/helical_wheel.php). The procedure was then repeated for human 
ANXA1, but with this gene it was not necessary to exclude fish from the alignment. 
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Neuropathology 
Brain tissue samples in 10% formalin-fixed, paraffin-embedded tissue blocks were available from the 
London Neurodegenerative Diseases Brain Bank (King’s College London, UK). Consent for autopsy, 
neuropathological assessment and research were obtained from all subjects and all studies were 
carried out under the ethical approval of the tissue bank. Block taking for histological and 
immunohistochemical studies and neuropathological assessment for neurodegenerative diseases was 
performed in accordance with standard criteria. 
Immunohistochemistry: 
Immunohistochemistry was carried out as per previously published protocols [33]. In brief, sections of 
7µm thickness were cut from the paraffin-embedded tissue blocks, deparaffinised in xylene, 
endogenous peroxidase was blocked by 2.5% H2O2 in methanol and immunohistochemistry 
performed. To enhance antigen retrieval, sections were kept in citrate buffer for 10 minutes following 
microwave treatment. After blocking in normal serum primary antibody was applied overnight at 4qC.  
Following washes, sections were incubated with biotinylated secondary antibody (DAKO), followed by 
avidin:biotinylated enzyme complex (Vectastain Elite ABC kit, Vector Laboratories, Peterborough, UK). 
Finally sections were incubated for 10–15 min with 0.5 mg/mL 3,3′-diaminobenzidine chromogen 
(Sigma-Aldrich Company Ltd, Dorset UK) in Tris-buffered saline (pH 7.6) containing 0.05% H2O2. 
Sections were counterstained with Harris’ haematoxylin and immunostaining analysed using a Leica 
microscope (Leica, Wetzlar, Germany).  
Double Immunofluorescence: 
7µm sections were cut from formalin fixed paraffin embedded blocks, dewaxed in xylene and 
dehydrated in 99% industrial methylated spirit. Sections were then pretreated by microwaving in 
citrate buffer and blocked using normal goat serum (1:10 for 45min). Primary antibodies were then 
applied and sections incubated at 4°C overnight. Sections were washed and secondary Alexa Fluor 
antibody (Invitrogen, Paisley, UK) applied for 45 min (in dark). Autofluorescence was quenched by 
incubating the sections in Sudan black for 10min followed by numerous washes in phosphate 
buffered saline before coverslip mounting using hard set media with DAPI. Sections were visualised 
using a fluorescent microscope (Zeiss Axiovert S 100, Gottingen, Germany) and images captured using 
ImagePro Express (V6). 
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Figure Legends 
 
Main Figures 
 
Figure 1. Annexin A11 mutations identified in ALS patients following stringent filtering of 
exome sequencing data. (A and B) Pedigrees of Family 1 and 2 respectively, carrying the 
p.D40G mutation. Family members for whom DNA was available for segregation analysis are 
labelled with M/W for a heterozygous mutant (A>G allele) or W/W for a homozygous 
reference allele. The gender has been anonymised for each individual.  Affected individuals 
with ALS are denoted by a solid black diamond, unaffected by white diamonds and 
unaffected carriers with a black dot. . Index cases exome sequenced as part of this study are 
marked with a blue star. (C) The G175R mutation segregates in both an index case and 
affected sibling. (D) Schematic representation of the Annexin A11 molecule highlighting a 
clustering of mutations in the N-terminus (first 196 residues). Mutation positions in the N-
terminus are fully conserved in mammals, and conserved in birds, amphibians and reptiles if 
in an annexin domain. Mutations identified in the discovery cohort are red, replication 
cohort blue and those found in sporadic ALS cases yellow. The binding site of calcyclin 
(labelled CACY) is located in the N-terminus, residues 50-62. 
 
Figure 2. TDP-43 and Annexin A11 immunohistochemistry from post-mortem spinal cord 
tissue of a SALS cases harbouring the novel D40G mutation. (A) phospho-TDP43 positive 
cytoplasmic inclusion from anterior horn of the spinal cord.  (B-E) Annexin A11 positive 
inclusions in motor neurons of the cord included skein like (B), filamentous and tubular- 
shaped structures (C-D). Occasional more “basket-like” inclusions were seen in the cord (E).  
(F) Abundant annexin A11 positive torpedo-like neuritic structures were also present in the 
neuropil here seen in the motor cortex. (arrows) (G-H) Representative spinal cord staining in 
a SALS case (n=4) negative for Annexin A11 mutations and known ALS mutations and a 
control individual (n=4). (I-J) Double labelling for phospho-TDP43 (green) and Annexin A11 
aggregates (red). (K-L) Co-staining for ubiquitinated aggregates (red= Annexin A11 and 
green=ubiquitin) showed occasional co-localisation (indicated by arrows). Scale bars - A,E,G 
and  H- 30µm; B, C- 20µm; D-15µm; F 50µm, I,J- 25µm, K,L- 50µm. 
 
Figure 3. Functional Annexin A11 studies in mouse Primary Motor Neurones and SH-SHSY 
cells. (A) ANXA11-HAWT/G38R/D40G/R235Q transfected into PMNs display cytoplasmic vesicle-like 
structures for WT, G38R and D40G and a significant localization of smaller cytoplasmic foci in 
the cytoplasm, (B) p=0.0004 (One way ANOVA and Dunnett's post hoc test, Bars represent 
mean and SEM ). Vesicles were defined as structures with a diameter between 0.5µm to 1.9 
µm (mean 1 µm) and foci 0.16µm to 0.5 µm (mean 0.3 µm).  (C) There was a significant 
proportion of foci associated with R235Q (p<0.0001, One way ANOVA and Dunnett's post 
hoc test) but a smaller proportion of vesicle like structures associated with G38R and a 
complete absence with R235Q (p=0.0051 and p<0.0001 respectively, One way ANOVA and 
Dunnett's post hoc test). (D) Co-expression of ANXA11-HAWT and ANXA11-GFPR235Q in SH-
SHSY cells demonstrated co-localisation suggesting sequestering of ANXA11-HAWT by mutant 
ANXA11, possibly acting in a dominant negative manner. (E) Co-expression of ANXA11-
HAWT/G38R/D40G/R235Q with the C-terminal fragment of TDP-43-GFP (residues 208-414), showing 
a significant co-localization of R235Q with TDP43 (p=0.0003, One way ANOVA and Dunnett's 
post hoc test) and a significant engulfment of D40G by TDP43 (p=0.001 One way ANOVA and 
Dunnett's post hoc test). Scalebars (A,D and E) 10µm. 
 
15  
Figure 4. Calcyclin analysis: in-vitro binding assays with mutant Annexin A11 constructs 
and staining of post-mortem tissue. (A) Representational western blot demonstrating lack 
of binding of FLAG-calcyclin to ANXA11-GFPD40G, ANXA11-GFPG189E and ANXA11-GFPR235Q by 
immunoprecipitation (n=3). The top panel shows GFP intensities of input and pulled down 
fractions, with IgG heavy (50kDA) and light (25kDa) chains indicated. The bottom panel 
illustrates input and IP levels of FLAG-calcyclin. (B) Cross-section of spinal cord showing 
calcyclin expression in (i) control and (ii) SALS case with the p.D40G mutation. High calcyclin 
expression can be seen in the lateral corticospinal tracts (arrows). High magnification 
revealed glial and neuropil staining in the lateral corticospinal tract (data not shown).  (iii) 
SALS case devoid of known ALS causing mutation but also displaying strong expression of 
calcyclin in the lateral corticospinal tracts (arrows). Scale bars (i) 40µm, (ii) 30µm and (iii) 
25µm (C) NP40 insolubility assay of co-expression of 500ng of ANXA11-GFPWT and ANXA11-
GFPR235Q and 500ng of FLAG-calcyclin (labelled C in image) in HEK cells, demonstrating 
clearance of insoluble R235Q aggregates by calcyclin co-expression. An equivalent amount 
of empty GFP Vector (500ng) was added to untreated WT and R235Q HEK cells. (D) 
Quantification of ANXA11-GFPWT and R235Q co-expression experiment. Bands were quantified 
with ImageJ (http://imagej.nih.gov/ij/) and intensity levels were calculated with respect to 
untreated ANXA11-GFPWT and a one-way ANOVA test demonstrating significance of the 
R235Q untreated and R235Q treatment with calcyclin and MG132 treatment for 24hours 
(p<0.01 and p<0.001 respectively). 
 
Supplementary Figures 
 
Supplementary Figure 1. The Annexin A11 p.D40G mutation shares a common haplotype 
comprised of 8 SNPs and 2 microsatellites. Micro 1 and Micro 2 are two uncharacterised tri 
and di nucleotide repeat sequences identified from the hg19 reference genome 
(genome.ucsc.edu). Shaded yellow region denotes the region containing the Annexin A11 
gene. The common conserved haplotype in members with the D40G mutation is indicated 
by a grey bar. Individuals with Annexin A11 mutations are labeled according to 
Supplementary Table 3. 
 
Supplementary Figure 2. R235Q ANXA11-GFP co-localises with ubiquitin and p62 in HEK 
cells. Cells were transfected with ANXA11-GFPR235Q for 48hrs, fixed and stained with the 
following antibodies (A) mouse GFP green. (B) ANXA11 Polyclonal rabbit Antibody 
(Proteintech) red. (C) Merge of A, B and DAPI blue nuclear staining, showing specificity of 
ANXA11 specific antibody. , (D) mouse GFP green. (E) Rabbit K-48 Ubiquitin red. (F) Merge of 
D, E and DAPI. (G) mGFP green. (H) Rabbit p62 red. (I) Merge of G, H and DAPI. 
 
Supplementary Figure 3. R235Q ANXA11-GFP forms high molecular weight detergent 
resistant aggregates in HEK cells. (A) The lysate (L), soluble (S) and insoluble (I) fractions of 
HEK cells transfected with ANXA11-GFPWT/G38R/D40G/G189E/R235Q shows R235Q to form high 
detergent resistant insoluble aggregates. (B) The level of R235Q insoluble fraction is 
statistically significant when compared with WT (p=0.007, One way ANOVA with Dunnett’s 
post hoc test). 
 
Supplementary Figure 4. Cell survival assay of ANXA11-GFP WT and mutant constructs 
shows R235Q to be toxic in SH-SHSY cells. SH-SHSY cells transfected with ANXA11-GFP 
empty vector, WT and mutant constructs were harvested at 48hrs post transfection and the 
percentage of GFP positive apoptotic cells determined by FACS analysis. (n=3). ANXA11-
R235Q was the only mutant to be statistically significant compared to WT (p=0.0001, one 
way ANOVA with Dunnett’s post hoc test). 
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Supplementary Figure 5. Modelling of Annexin A11 identifies two amphipathic helices in 
the N-terminus of Annexin A11 that overlap the G38 and D40 residues. (A) Jpred secondary 
structure prediction focusing on the N-terminus (residues 1-270) using a multiple alignment 
of all mammalian orthologue sequences identified two amphipathic helices, indicated in red 
(residues 38-45 and 50-60). Known annexin domains start at ~200 residues. The locations of 
the G38 and D40 residues are indicated in the first amphipathic helix. (B) Protein structure of 
Annexin A1 (pdb:1hm6) in the presence of calcium, with the annexin domain alpha helices in 
red and the N-terminal helices in magenta. (C) Jpred also predicts the N-terminus of Annexin 
A1 to possess two amphipathic helices (residues 2-14 and 19-26). (D) Jpred predicts the 
G38R variant to change the first amphipathic helix to a beta-sheet whilst the D40G variant 
also severely disrupts it. 
 
Supplementary Figure 6. N-terminal Annexin A11 mutations do not alter binding of Sorcin 
and ALG2. (A) Immunoprecipitation (IP) of FLAG-Sorcin from mixed lysates of HEK cells 
transfected with ANXA11-GFPWT+G38R+D40G+G189E+R235Q activated with calcium show no 
difference in binding between ANXA11 WT and mutants when probed for GFP. (B) The same 
was seen when IP was conducted with ALG2-sorcin. (n=3). The top panel shows GFP 
intensities of input and pulldown fractions, with IgG heavy and light chains indicated. The 
bottom panel for both (A) and (B) illustrates input and IP levels of FLAG-sorcin or FLAG-ALG2 
respectively. 
 
Supplementary Tables 
 
Supplementary Table 1. Analysis of FALS exomes identifies 12 known ALS mutations and 
95 novel variants shared by two or more index cases. Twelve previously identified disease 
causing mutations (all from SOD1, FUS or TARDBP, shaded in grey) were identified in two or 
more of 713 FALS index cases, after stringent quality filtering and exclusion of variants found 
in >60,000 control exomes. When the 105 samples with a known ALS mutation were 
removed, there were 95 novel variants shared by two or more of the remaining 608 FALS 
cases.  
 
Supplementary Table 2. All ANXA11 variants identified in in discovery and replication FALS 
cohorts and UK SALS cases. The ATG of ANXA11 cDNA is defined as +1 according to HGVS 
guidelines (http://www.hgvs.org/), Refseq NM_145869. A high depth (mean of 63.3 reads) 
and degree of coverage (>10X in over 91% of samples) was observed in exome sequencing 
reads across the ANXA11 coding region. Frequencies for each variant were assessed in 
dbSNP132, ESP, ExAC, 1000 Genomes, UK10K, and also 672 non-neurological Kings College 
London (KCL) exomes. An additional 909 and 3596 UK local and Italian exome controls 
respectively were used to further assess frequencies for the p.G38R, D40G, P108L, G175R, 
G189E, R235Q and R346C variants. Polyphen predicts most ANXA11 novel mutations to be 
damaging. * Also harbored a C9ORF72 expansion. # Did not segregate in other affected 
family members, therefore are considered benign private polymorphisms.  na – not 
applicable. 
 
Supplementary Table 3. Clinical details of patients with ANXA11 mutations. Most patients 
with N-terminal mutations have late disease onset (average of 72years). Patients carrying a 
D40G mutation have predominantly bulbar onset. There was a distinct absence of FTD 
symptoms in all ANXA11 carriers. 
 
 
Supplementary Table 1. 95 Single nucleotide variants present in 2 or more FALS but absent in all control databases 
 
Chr Start (hg19) End (hg19) Gene Status Gene AA Change cdna change Exon LongRef_Details FALS_index_hets Discovery Replication 
21 33039672 33039672 Known SOD1 I114T 341T>C exon4 154:NP_000445:NM_000454 10 9 1 
1 11082610 11082610 Known TARDBP A382T 1144G>A exon6 414:NP_031401:NM_007375 6 1 5 
21 33032096 33032096 Known SOD1 A5V 14C>T exon1 154:NP_000445:NM_000454 5 3 2 
16 31202739 31202739 Known FUS R521C 1561C>T exon15 526:NP_004951:NM_004960 4 3 1 
1 11082475 11082475 Known TARDBP M337V 1009A>G exon6 414:NP_031401:NM_007375 3 3 0 
16 31202752 31202752 Known FUS P525L 1574C>T exon15 526:NP_004951:NM_004960 3 2 1 
21 33039612 33039612 Known SOD1 G94D 281G>A exon4 154:NP_000445:NM_000454 3 1 2 
1 11082536 11082536 Known TARDBP G357D 1070G>A exon6 414:NP_031401:NM_007375 2 2 0 
16 31202282 31202282 Known FUS   1394-2A>- exon14 526:NP_004951:NM_004960 2 1 1 
21 33040861 33040861 Known SOD1 L145F 435G>C exon5 154:NP_000445:NM_000454 2 1 1 
1 11082501 11082501 Known TARDBP N345K 1035C>A exon6 414:NP_031401:NM_007375 2 0 2 
21 33039677 33039677 Known SOD1 R116G 346C>G exon4 154:NP_000445:NM_000454 2 0 2 
21 28212087 28212087 Novel ADAMTS1   1853-6T>A exon8 967:NP_008919:NM_006988 2 1 1 
14 78325590 78325590 Novel ADCK1 R131C 391C>T exon4 523:NP_065154:NM_020421 2 2 0 
14 96944819 96944819 Novel AK7 D525H 1573G>C exon15 723:NP_689540:NM_152327 2 1 1 
9 116151928 116151928 Novel ALAD R222H 665G>A exon9 330:NP_000022:NM_000031 2 1 1 
10 81930608 81930608 Novel ANXA11 D40G 119A>G exon5 505:NP_665876:NM_145869 3 2 1 
10 99016185 99016185 Novel ARHGAP19   841-24T>G exon7 494:NP_116289:NM_032900 2 2 0 
3 35833976 35833976 Novel ARPP21 P713L 2138C>T exon18 813:NP_001254548:NM_001267619 3 2 1 
19 57746688 57746688 Novel AURKC P278L 833C>T exon7 309:NP_001015878:NM_001015878 2 1 1 
9 136910498 136910498 Novel BRD3 A378T 1132G>A exon7 726:NP_031397:NM_007371 2 1 1 
9 116132106 116132106 Novel BSPRY Y298C 893A>G exon6 402:NP_060158:NM_017688 2 2 0 
6 41898380 41898380 Novel BYSL S193F 578C>T exon4 437:NP_004044:NM_004053 2 0 2 
7 143002126 143002126 Novel CASP2 R441S 1321C>A exon11 452:NP_116764:NM_032982 2 0 2 
10 33000644 33000644 Novel CCDC7 G159E 476G>A exon7 628:NP_078964:NM_024688 2 0 2 
3 112066521 112066521 Novel CD200 E180K 538G>A exon4 269:NP_005935:NM_005944 2 2 0 
17 72469704 72469704 Novel CD300A V24L 70G>T exon2 299:NP_009192:NM_007261 2 2 0 
9 123230234 123230234 Novel CDK5RAP2 D670E 2010C>A exon18 1893:NP_060719:NM_018249 2 2 0 
2 233398802 233398802 Novel CHRND K403N 1209G>T exon10 517:NP_000742:NM_000751 2 1 1 
12 8612225 8612225 Novel CLEC6A K52Q 154A>C exon3 209:NP_001007034:NM_001007033 2 0 2 
18 641356 641356 Novel CLUL1 E342Q 1024G>C exon7 466:NP_954636:NM_199167 2 2 0 
10 96535245 96535245 Novel CYP2C19 R144S 430C>A exon3 490:NP_000760:NM_000769 2 1 1 
14 73425415 73425415 Novel DCAF4 P464S 1390C>T exon14 495:NP_056419:NM_015604 2 2 0 
9 1056381 1056381 Novel DMRT2 A265D 794C>A exon4 561:NP_870987:NM_181872 2 2 0 
10 70182518 70182518 Novel DNA2 R780W 2338C>T exon15 1060:NP_001073918:NM_001080449 2 1 1 
16 84188196 84188196 Novel DNAAF1 E123K 367G>A exon4 725:NP_848547:NM_178452 2 2 0 
20 35399515 35399515 Novel DSN1 S39F 116C>T exon3 356:NP_079194:NM_024918 2 2 0 
8 27957346 27957346 Novel ELP3 V41M 121G>A exon3 547:NP_060561:NM_018091 2 2 0 
10 119307652 119307652 Novel EMX2 Q223L 668A>T exon3 252:NP_004089:NM_004098 2 2 0 
11 6232756 6232756 Novel FAM160A2 C981R 2941T>C exon12 986:NP_115503:NM_032127 2 2 0 
Chr Start (hg19) End (hg19) Gene Status Gene AA Change cdna change Exon LongRef_Details FALS_index_hets Discovery Replication 
2 242431003 242431003 Novel FARP2 G899E 2696G>A exon24 1054:NP_055623:NM_014808 2 2 0 
3 13679370 13679370 Novel FBLN2 T1169I 3506C>T exon17 1184:NP_001989:NM_001998 2 2 0 
4 155505337 155505337 Novel FGA R847K 2540G>A exon6 866:NP_000499:NM_000508 2 2 0 
1 27942290 27942290 Novel FGR G250S 748G>A exon8 529:NP_005239:NM_005248 2 2 0 
12 8196678 8196678 Novel FOXJ2 S203R 609C>G exon5 574:NP_060886:NM_018416 2 1 1 
1 74670585 74670585 Novel FPGT L298R 893T>G exon4 594:NP_003829:NM_003838 2 2 0 
10 35929469 35929469 Novel FZD8 S297T 889T>A exon1 694:NP_114072:NM_031866 2 2 0 
10 35929468 35929468 Novel FZD8 S297F 890C>T exon1 694:NP_114072:NM_031866 2 2 0 
4 47427769 47427769 Novel GABRB1 V387M 1159G>A exon9 474:NP_000803:NM_000812 2 2 0 
2 233671276 233671276 Novel GIGYF2 A593V 1778C>T exon17 1320:NP_001096617:NM_001103147 2 1 1 
12 133353644 133353644 Novel GOLGA3 A1252V 3755C>T exon20 1498:NP_005886:NM_005895 2 2 0 
12 14834362 14834362 Novel GUCY2C G221S 661G>A exon5 1073:NP_004954:NM_004963 2 2 0 
1 24144010 24144010 Novel HMGCL V70L 208G>C exon3 325:NP_000182:NM_000191 2 1 1 
3 50326753 50326753 Novel IFRD2 S337I 1010G>T exon8 506:NP_006755:NM_006764 2 2 0 
4 143326459 143326459 Novel INPP4B A52G 155C>G exon7 924:NP_003857:NM_003866 2 2 0 
2 160968716 160968716 Novel ITGB6   1568-6C>G exon13 na 2 1 1 
19 54871655 54871655 Novel LAIR1 P130L 389C>T exon4 287:NP_002278:NM_002287 2 1 1 
5 154173227 154173227 Novel LARP1 R194H 581G>A exon5 1019:NP_056130:NM_015315 2 1 1 
15 101550975 101550975 Novel LRRK1 S405F 1214C>T exon9 2015:NP_078928:NM_024652 2 2 0 
11 24750759 24750759 Novel LUZP2 K36R 107A>G exon2 346:NP_001009909:NM_001009909 2 2 0 
X 151092183 151092183 Novel MAGEA4 V16A 47T>C exon3 317:NP_002353:NM_002362 2 2 0 
1 118009038 118009038 Novel MAN1A2 R386H 1157G>A exon8 641:NP_006690:NM_006699 2 1 1 
13 113743978 113743978 Novel MCF2L D963E 2889C>A exon26 1125:NP_001106203:NM_001112732 2 0 2 
22 20939211 20939211 Novel MED15 V585I 1753G>A exon14 748:NP_056973:NM_015889 2 1 1 
7 100839620 100839620 Novel MOGAT3 L240R 719T>G exon6 341:NP_835470:NM_178176 2 2 0 
11 60291368 60291368 Novel MS4A13   130-2A>T exon4 112:NP_001094379:NM_001100909 2 2 0 
16 70712181 70712181 Novel MTSS1L F200V 598T>G exon8 747:NP_612392:NM_138383 2 2 0 
1 148252811 148252811 Novel NBPF14 K2712I 8135A>T exon65 921:NP_056198:NM_015383 2 2 0 
1 148591281 148591281 Novel NBPF15 D449A 1346A>C exon15 670:NP_775909:NM_173638 2 2 0 
19 15292547 15292547 Novel NOTCH3 G878R 2632G>C exon17 2321:NP_000426:NM_000435 2 1 1 
10 45799147 45799147 Novel OR13A1 S242G 724A>G exon4 328:NP_001004297:NM_001004297 2 1 1 
14 20482665 20482665 Novel OR4K14 A230P 688G>C exon1 310:NP_001004712:NM_001004712 2 2 0 
11 6191099 6191099 Novel OR52B2 R153Q 458G>A exon1 323:NP_001004052:NM_001004052 2 0 2 
1 36884605 36884605 Novel OSCP1 I337T 1010T>C exon9 379:NP_659484:NM_145047 2 0 2 
12 121666658 121666658 Novel P2RX4 M246V 736A>G exon7 388:NP_002551:NM_002560 2 2 0 
12 103306691 103306691 Novel PAH   61-15C>A exon3 452:NP_000268:NM_000277 2 1 1 
8 22447189 22447189 Novel PDLIM2 R483L 1448G>T exon8 602:NP_067643:NM_021630 2 0 2 
11 17167247 17167247 Novel PIK3C2A H558Y 1672C>T exon7 1686:NP_002636:NM_002645 2 2 0 
21 46697019 46697019 Novel POFUT2 E248D 744G>C exon6 429:NP_598368:NM_133635 2 1 1 
10 45484756 45484756 Novel RASSF4 T189I 566C>T exon7 321:NP_114412:NM_032023 2 2 0 
18 20573246 20573246 Novel RBBP8 V486M 1456G>A exon11 897:NP_976036:NM_203291 2 2 0 
17 6917595 6917595 Novel RNASEK M135K 404T>A exon3 137:NP_001004333:NM_001004333 2 2 0 
18 13731682 13731682 Novel RNMT A56T 166G>A exon3 476:NP_003790:NM_003799 2 2 0 
14 94915009 94915009 Novel SERPINA11 P35T 103C>A exon2 422:NP_001073920:NM_001080451 2 2 0 
Chr Start (hg19) End (hg19) Gene Status Gene AA Change cdna change Exon LongRef_Details FALS_index_hets Discovery Replication 
19 4362692 4362692 Novel SH3GL1 P257R 770C>G exon8 368:NP_003016:NM_003025 2 2 0 
8 145153884 145153884 Novel SHARPIN C354Y 1061G>A exon8 387:NP_112236:NM_030974 2 2 0 
9 94809966 94809966 Novel SPTLC1 A305T 913G>A exon10 473:NP_006406:NM_006415 2 2 0 
1 47737850 47737850 Novel STIL D761N 2281G>A exon13 1288:NP_001041631:NM_001048166 2 1 1 
22 24580184 24580184 Novel SUSD2 T174A 520A>G exon4 822:NP_062547:NM_019601 2 2 0 
3 33249395 33249395 Novel SUSD5 S105N 314G>A exon3 629:NP_056366:NM_015551 2 2 0 
16 71602673 71602673 Novel TAT D389N 1165G>A exon11 454:NP_000344:NM_000353 2 1 1 
6 46660378 46660378 Novel TDRD6 I1505V 4513A>G exon1 2096:NP_001010870:NM_001010870 2 2 0 
8 42693473 42693473 Novel THAP1 D92Y 274G>T exon3 213:NP_060575:NM_018105 2 1 1 
3 156396031 156396031 Novel TIPARP I182T 545T>C exon2 657:NP_056323:NM_015508 2 2 0 
2 171974346 171974346 Novel TLK1 S54T 161G>C exon2 766:NP_036422:NM_012290 2 0 2 
17 42092217 42092217 Novel TMEM101 L35P 104T>C exon1 257:NP_115752:NM_032376 2 1 1 
9 74360477 74360477 Novel TMEM2 D164G 491A>G exon4 1383:NP_037522:NM_013390 2 2 0 
17 7572979 7572979 Novel TP53 T377I 1130C>T exon11 393:NP_000537:NM_000546 2 0 2 
16 1306562 1306562 Novel TPSD1 E43G 128A>G exon2 242:NP_036349:NM_012217 2 0 2 
16 1306564 1306564 Novel TPSD1 A44P 130G>C exon2 242:NP_036349:NM_012217 2 0 2 
2 178417073 178417073 Novel TTC30B P140Q 419C>A exon1 665:NP_689730:NM_152517 2 1 1 
19 17758154 17758154 Novel UNC13A A655V 1964C>T exon16 1703:NP_001073890:NM_001080421 2 2 0 
19 17716941 17716941 Novel UNC13A D1678E 5034C>A exon42 1703:NP_001073890:NM_001080421 2 2 0 
9 96030059 96030059 Novel WNK2 R1243Q 3728G>A exon16 2217:NP_006639:NM_006648 2 2 0 
10 286903 286903 Novel ZMYND11 Y275F 824A>T exon9 602:NP_006615:NM_006624 2 2 0 
12 133780923 133780923 Novel ZNF268 R884I 2651G>T exon6 947:NP_003406:NM_003415 2 2 0 
17 18566459 18566459 Novel ZNF286B S120R 360C>A exon5 522:NP_001138517:NM_001145045 2 2 0 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 2. All ANXA11 variants found in index FALS and SALS cases with control frequencies, including exome depth and coverage information 
Genomic 
Position Ref  Var  Exon Change cDNA  
Amino 
Acid Novelty 
FALS 
Index 
Hets 
All 
FALS>10x 
ALL 
FALS 
Av 
Depth 
KCL 
Hets dbSNP142 
1000 
Genomes 
Italian 
Control 
Exomes 
(n=3596) 
Italian 
Control 
Exomes 
Av 
Depth 
UK10K  
(n=3781) EVS_EU_Coverage 
EVS 
EU 
Hets 
ExAC_ALL ExAC (EU) ALSDB SIFT Polyphen  
81932595 G A 4 Nonsynon 23C>T P8L na 8 880 78 9 rs147334030 0.0021965     53 4300 67 870 758 15 T:0.03 D:1.0 
81930615 C T 5 Nonsynon 112G>A G38R na 2 877 73 0 rs142083484 0 0 89 1 4300 1 6 5 0 D:0.01 D:1.0 
81930608 T C 5 Nonsynon 119A>G D40G NOVEL 3 878 75 0 na 0 0 89 0 4300 0 None None 0 T:0.78 D:0.996 
81929047 GCCCCAGGG - 6 Non-fshift deletion 231_239del 77_80del na 0 562 18 0 na 0     0 4228 0 10 0 0 na na 
81929022 G A 6 Synon 264C>T G88G na 1 575 16 0 rs138254262 0.0009984     0 4169 1 32 3 0 D:0 na 
81928983 A G 6 Syno 303T>C P101P na 27 674 16 14 rs11542746  0.0031949     160 4207 102 1142 955 46 na na 
81928963 G A 6 Nonsynon 323C>T P108L# na 0 701 17 0 na 0 0    0 4245 0 None None 0 T:0.64 T:0.92 
81928915 G A 6 Nonsynon 371C>T P124L# na 1 715 22 0 na 0     0 4258 0 2 1 0 D:0.01 D:0.994 
81928830 G A 6 Synon 456C>T Y152Y na 26 762 40 12 rs34003188 0.0087859     99 4295 155 1269 964 36 na na 
81928812 C A 6 Synon 474G>T V158V na 3 774 45 1 rs139412104 0.0019968     8 4293 22 183 143 6 na na 
81928763 C T 6 Nonsynon 523G>A G175R NOVEL 1 745 38 0 na 0 0 19 0 4291 0 0 None 1 T:0.11 T:0.005 
81927065 C T 7 Nonsynon 566G>A G189E* na 0 864 50 na rs569546089 0 1 63 0 4300 0 17 14 1 T:0.18 D:0.999 
81927059 C T 7 Nonsynon 572G>A R191Q na 86 863 53 80 rs2229554 0.0219649     521 4300 547 6073 4702 202 T:0.48 D:1.0 
81927002 C T 7 Nonsynon 629G>A R210Q na 1 876 67 3 rs147610631 0.0013978     5 4300 12 138 72 1 D:0.01 D:0.995 
81926736 C T 8 Synon 654G>A T218T na 1 825 61 0 rs200066001 0     0 4300 0 6 5 0 na na 
81926718 A G 8 Synon 672T>C I224I na 173 836 76 134 rs2228427 0.108427     1019 4300 1063 15140 8078 343 na na 
81926702 G A 8 Nonsynon 688C>T R230C na 357 837 85 268 rs1049550 0.392173     3157 4300 2041 45030 24922 649 D:0.01 D:1.0 
81926686 C T 8 Nonsynon 704G>A R235Q NOVEL 0 836 94 na na 0 0 22 0 4300 0 0 0 0 D:0 D:1.0 
81926659 G A 8 Nonsynon 731C>T T244M na 3 824 90 3 rs41310298 0.0017971     22 4300 30 203 175 9 D:0 D:1.0 
81925945 G T 9 Synon 753C>A I251I NOVEL 0 876 59 0 na 0     0 4300 0 None None 0 na na 
81925903 T C 9 Synon 795A>G T265T na 1 882 81 0 rs150935845 0     1 4300 6 17 14 0 na na 
81925902 T C 9 Nonsynon  796A>G I266V na 0 882 81 0 na 0     0 4300 0 1 0 0 T:0.33 T:0.284 
81925866 T C 9 Nonsynon  832A>G I278V na 7 879 72 8 rs72807973 0.0023962     33 4300 42 363 281 20 T:0.15 T:0.018 
81923347 C T 11 Synon 972G>A E324E na 1 825 93 0 rs146139449 0     0 4287 1 1 1 0 na na 
81923155 G A 12 Nonsynon 1036C>T R346C NOVEL 1 883 108 0 na 0 0 58 0 4300 0 0 None 0 D:0 D:1.0 
81921766 C T 13 Nonsynon  1105G>A E369K na 5 827 56 4 rs34414015 0.0017971     42 4300 50 488 400 14 D:0 D:1.0 
81918880 G A 14 Synon 1252C>T L418L na 3 874 71 0 rs61860018 0.0001997     5 4300 10 46 42 3 na na 
81917486 T C 16 Nonsynon  1369A>G I457V na 13 885 95 8 rs1802932 0.0033946     94 4300 103 1086 764 43 T:0.32 T:0.409 
81917463 G A 16 Synon 1392C>T T464T na 1 887 106 0 rs374382845 0     1 4300 1 4 3 0 na na 
 
 Supplementary Table 3. Clinical details of patients with ANXA11 mutations. 
 
 
 
Patient Cohort Mutation Gender FALS / SALS Age of onset (years) 
Site of onset 
(Limb / Bulbar) 
Disease 
Duration 
(months) 
FTD (Y/N) 
Patient 1 F1 III:2 Discovery p.D40G F FALS 74 BULBAR 60 N 
Patient 2 F2 III:19 Discovery p.D40G F FALS 70 LIMB 72 N 
Patient 3 Replication p.D40G F FALS 55 BULBAR - N 
Patient 4 F1 III:5 Discovery p.D40G F FALS 72 BULBAR - N 
Patient 5 F2 II:2 Discovery p.D40G M FALS 83 BULBAR 24 N 
Patient 6 Discovery p.G38R M FALS 50 MIXED 12 N 
Patient 7 Discovery p.G38R M FALS 62 LIMB ALIVE N 
Patient 8 Replication p.G175R M FALS 61 LIMB - N 
Patient 9 Replication p.R346C M FALS 74 LIMB 181 N 
Patient 10 Sporadic p.D40G M SALS 72 BULBAR 36 N 
Patient 11 Sporadic p.G189E M SALS 53 LIMB 24 N 
Patient 12 Sporadic p.R235Q F SALS 65 BULBAR 24 N 
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Figure 1. Annexin A11 mutations identified in ALS patients following stringent filtering of exome sequencing data.  
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Figure 2. TDP-43 and Annexin A11 immunohistochemistry from post-mortem spinal 
cord tissue of a SALS case harbouring the novel D40G mutation.  
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Supplementary Figure 1.  
The Annexin A11 p.D40G mutation shares a common haplotype comprised of 8 SNPs and 2 
microsatellites.  
D40G 
Sporadic  FAMILY 2 – D40G G38R 
G38R 
Marker Position (Ch 10) Change MAF Individual III:2 Individual III:5 Individual II:2 Individual II:19 Patient 10 Patient 6 Patient 7 
rs185034903 82007218 C>T 0.07 C          T C          T C          T C          T C          T C          C C          C 
rs148817640 82005957 C>G 0.07 C          G C          G C          G C          G C          G C          C C          C 
Micro1 81991564 (TTG)n na 303      312 303      312 306      312 303      312 306      312       300      306       303      324 
rs11202162 81977939 C>A 0.09 C          A C          A C          A C          A C          A C          C C          C 
rs73299551 81955112 A>G 0.107 A          G A          G A          G A         G A         G 
 
A          A A          A 
Micro2 81947737 (AT)n na 208      196 208      196 180      196 212      196 200      196 186       186 196        216 
ANXA11 A>G 81930608 A>G Novel A          G A          G A          G A          G A          G A          A A          A 
rs41310300 81926538 C>T 0.12 C          T C          T C          T C          T C          T C          C C          C 
rs73299508 81912409 G>C 0.12 G          C G         C G          C G         C G         C G          G G         C 
           
rs2184702 81906299 T>G 0.11 T          G T          G T          G T         G T         G 
 
G          G  T         G 
  
rs41291392 81904645 C>T 0.11 C          T C          T C          T C         T           C         T C          C C          C 
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Supplementary Figure 2. R235Q ANXA11-GFP co-localises with ubiquitin and p62 in HEK cells.  
*** 
Supplementary Figure 3 – R235Q ANXA11-GFP forms high molecular 
weight detergent resistant aggregates in HEK cells 
Supplementary Figure 4. Cell survival assay of ANXA11-GFP WT and mutant 
constructs shows R235Q to be toxic in SH-SHSY cells 
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Supplementary Figure 5. Modelling of Annexin A11 identifies two amphipathic helices 
in the N-terminus of Annexin A11 that overlap the G38 and D40 residues.  
Supplementary Figure 6. N-terminal Annexin A11 mutations do not alter  
binding of Sorcin and ALG2.  
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